NPZ-24460-96098
5 vaccinations
2 coded responses
57 check-ins
2 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 482 / MI
- Registered
- 2020-12-27
- Relationship
- Self
- Race
- White
- Ethnicity
- Hispanic or Latino
Timeline
-
2020-12-27
Registered in v-safe
-
2020-12-27
Dose 1 — Pfizer-BioNTech
- 2020-12-27
- 2020-12-28
- 2020-12-29
- 2020-12-30
- 2020-12-31
- 2021-01-01
- 2021-01-02
- 2021-01-03
- 2021-01-10
-
2021-01-17
Dose 2 — Pfizer-BioNTech
- 2021-01-24
- 2021-01-31
- 2021-02-07
- 2021-02-14
- 2021-02-21
- 2021-02-28
- 2021-04-18
- 2021-07-18
-
2021-10-08
Dose 3 — Pfizer-BioNTech
- 2021-10-11
- 2021-10-12
- 2021-10-13
- 2021-10-14
- 2021-10-15
- 2021-10-22
- 2021-10-29
- 2021-11-05
- 2021-11-12
- 2021-11-19
- 2022-01-07
- 2022-04-08
-
2022-05-13
Dose 4 — Pfizer-BioNTech
- 2022-05-13
-
2022-05-14
Health check-in — days 1–6 daily, dose 4Feeling: Good · Site: Pain, Redness · Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2022-05-15
- 2022-05-16
- 2022-05-17
- 2022-05-18
- 2022-05-19
- 2022-05-20
- 2022-05-27
- 2022-06-03
- 2022-06-10
- 2022-06-17
- 2022-06-24
-
2022-08-12
Survey response — 3 months, dose 4MedDRA: Cough, Fatigue — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitFree text: Cough, fatigueMedDRA releases: 2024-11 · check-in free text available
-
2022-08-12
Report sent to call center — 3 months, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · Outpatient clinic or urgent care clinic visit · 1 call case(s)
-
2022-08-15
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2022-11-11
Dose 5 — Pfizer-BioNTech
- 2022-11-12
-
2022-11-13
Survey response — days 1–6 daily, dose 5MedDRA: Injection site bruising — Feeling: Good · Site: PainFree text: Small bruise at injection siteMedDRA releases: 2024-11 · check-in free text available
- 2022-11-14
- 2022-11-15
- 2022-11-16
- 2022-11-17
- 2022-11-18
- 2022-11-25
- 2022-12-02
- 2022-12-09
- 2022-12-16
- 2022-12-23
- 2023-02-10
- 2023-05-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-27 | Pfizer-BioNTech | |
| 2 | 2021-01-17 | Pfizer-BioNTech | |
| 3 | 2021-10-08 | Pfizer-BioNTech | No |
| 4 | 2022-05-13 | Pfizer-BioNTech | No |
| 5 | 2022-11-11 | Pfizer-BioNTech | No |
Call center
1 call center case
1 successful
Free text
Release 12 — 3 months, dose 4
Symptoms: Cough, fatigue
Release 12 — days 1–6 daily, dose 5
Systemic reaction (other): Small bruise at injection site
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SRO | Injection site bruising | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release